Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. Transactions on Cancer
  4. Vol 6, Issue 1, 2025

Clinical Study on the Heterogeneity Characteristics of Hepatobiliary Tumors and the Establishment of Individualized Treatment Strategies

Download as PDF

DOI: 10.23977/tranc.2025.060105 | Downloads: 7 | Views: 347

Author(s)

Guochao Li 1

Affiliation(s)

1 Department of Hepatobiliary and Pancreatic Surgery, Tongliao People's Hospital, Inner Mongolia Autonomous Region, Tongliao, Inner Mongolia, 028000, China

Corresponding Author

Guochao Li

ABSTRACT

This paper conducts a clinical study on personalized treatment based on tumor heterogeneity assessment. A total of 116 patients with liver and gallbladder tumors who visited the hepatobiliary surgery department of a public hospital from January 2022 to December 2024 were selected and randomly divided into a control group and an experimental group, with 58 cases in each group. Both groups received standard treatment; however, the experimental group, in addition to standard treatment, formulated personalized treatment strategies based on tumor heterogeneity assessment and molecular subtyping results. After three months of treatment, clinical indicators and efficacy were compared between the two groups. The experimental results showed that both groups improved clinically after treatment compared to before. Compared to the control group, the experimental group had a significantly lower rate of positive ROMs after three months of treatment. Moreover, stratified interventions based on heterogeneity characteristics demonstrated more significant improvements in treatment outcomes for patients with clonal target mutations, high tumor mutation burden, and portal vein cancer thrombi. Personalized treatment plans formulated based on tumor heterogeneity features can significantly improve symptoms, signs, and objective efficacy indicators in patients with liver and gallbladder tumors, providing new directions for optimizing clinical treatment strategies and offering potential for further promotion.

KEYWORDS

Tumor heterogeneity; hepatobiliary tumors; clinical efficacy; individualized treatment strategy; efficacy index

CITE THIS PAPER

Guochao Li, Clinical Study on the Heterogeneity Characteristics of Hepatobiliary Tumors and the Establishment of Individualized Treatment Strategies. Transactions on Cancer (2025) Vol. 6: 28-33. DOI: http://dx.doi.org/10.23977/tranc.2025.060105.

REFERENCES

[1] Chan S L, Wong N, Lam W K J, et al. Personalized treatment for hepatocellular carcinoma: Current status and future perspectives[J]. Journal of Gastroenterology and Hepatology, 2022, 37(7): 1197-1206.
[2] Zhang Y, You W H, Li X, et al. Single-cell RNA-seq reveals transcriptional landscape and intratumor heterogenicity in gallbladder cancer liver metastasis microenvironment[J]. Annals of Translational Medicine, 2021, 9(10): 889.
[3] Ali A, Ahmad E, Verma R, et al. Identification of therapeutic targets of gallbladder cancer using multi-omics approach[J]. Briefings in Functional Genomics, 2023, 22(2): 109-122.
[4] Sun Y, Gong J, Li Z, et al. Gallbladder cancer: surgical treatment, immunotherapy, and targeted therapy[J]. Postgraduate Medicine, 2024, 136(3): 278-291.
[5] Zhou Y, Yuan K, Yang Y, et al. Gallbladder cancer: current and future treatment options[J]. Frontiers in pharmacology, 2023, 14: 1183619.
[6] Rizzo A, Ricci A D, Gadaleta-Caldarola G, et al. Toward personalized therapy for cholangiocarcinoma: new insights and challenges[J]. Expert Review of Gastroenterology & Hepatology, 2021, 15(11): 1241-1243.
[7] Lendoire J, Gil L. Controversies and future directions in the management of gallbladder cancer[J]. Oncology and Translational Medicine, 2023, 9(4): 163-167.
[8] Pérez-Moreno P, Riquelme I, García P, et al. Environmental and lifestyle risk factors in the carcinogenesis of gallbladder cancer[J]. Journal of personalized medicine, 2022, 12(2): 234.
[9] Roa J C, García P, Kapoor V K, et al. Gallbladder cancer[J]. Nature reviews Disease primers, 2022, 8(1): 69.
[10] Pruthi H, Chabbra M, Soundararajan R, et al. Role of dual energy computed tomography in evaluation of suspected wall thickening type of gallbladder cancer[J]. Clinical and Experimental Hepatology, 2022, 8(1): 92-95.
[11] Barahona Ponce C, Scherer D, Brinster R, et al. Gallstones, body mass index, C‐Reactive protein, and gallbladder cancer: Mendelian randomization analysis of Chilean and European genotype data[J]. Hepatology, 2021, 73(5): 1783-1796.
[12] Rezvani Habibabadi R, Khoshpouri P, Ghadimi M, et al. Comparison between ROI-based and volumetric measurements in quantifying heterogeneity of liver stiffness using MR elastography[J]. European radiology, 2020, 30: 1609-1615.
[13] Xiao Y, Xiang C, Yang D, et al. Targeted-gene sequencing of an undifferentiated gallbladder carcinoma: a case report[J]. Diagnostic Pathology, 2020, 15: 1-6.
[14] Yang S, Feng H, Tian Y, et al. Unraveling early recurrence of risk factors in gallbladder cancer: a systematic review and meta-analysis[J]. European Journal of Surgical Oncology, 2024: 108372.
[15] Kam A E, Masood A, Shroff R T. Current and emerging therapies for advanced biliary tract cancers[J]. The lancet Gastroenterology & hepatology, 2021, 6(11): 956-969.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 1072
Visits: 75179

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.